/

Empresas

In

No verificado

Incyte

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

87 Comunicados de prensa

Ver todos los comunicados de prensa

05/01/2026

Ciencia

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

Industria

Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma

Fuente

Editor

1.00

0

22/12/2025

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

Fuente

Editor

1.00

0

22/12/2025

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Industria

Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

Fuente

Editor

1.00

0

18/12/2025

Eventos

Web y redes sociales

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

Incyte to Present at Upcoming Investor Conference

Fuente

Editor

1.00

0

18/12/2025

Eventos

Web y redes sociales

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

Incyte to Present at Upcoming Investor Conference

Fuente

Editor

1.00

0

17/12/2025

Industria

Oncología

Salud

Medicina - Varios

Sanidad

Farmacéutica

Biotecnología

Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Fuente

Editor

1.00

0

12/12/2025

Mercado laboral

Biotecnología

Salud

Farmacéutica

Medicina - Varios

Oncología

Incyte Announces Change to its Board of Directors

Fuente

Editor

1.00

0

08/12/2025

Eventos

Industria

Salud

Higiene alimentaria

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia

Fuente

Editor

1.00

0

07/12/2025

Web y redes sociales

Telefonía

Eventos

Industria

Oncología

Salud

Medicina - Varios

Farmacéutica

Cardiología

Biotecnología

Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

Fuente

Editor

1.00

0

07/12/2025

Eventos

Industria

Oncología

Salud

Higiene alimentaria

Medicina - Varios

Farmacéutica

Cardiología

Biotecnología

Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0